SA News • Jun. 18, 2012
From other sites
at MarketWatch.com (Aug 2, 2012)
at MarketWatch.com (Jun 14, 2011)
There are no Focus articles on KV.B.
There are no Transcripts on KV.B.
Jun. 18, 2012, 9:57 AMThe FDA says its analysis of compounded versions of the active ingredient in K-V Pharmaceuticals’ (KV.A -16.2%) Makena premature-birth prevention drug did not identify any major safety problems, but the agency reiterates that approved drugs are generally safer and more effective than compounded products. | Comment!
Oct. 13, 2011, 1:21 PMK-V Pharmaceutical (KV.A +22%) soars following a brief halt after it says information from two distinguished medical research bodies confirm that its FDA-approved Makena and unapproved compounded 17P formulations are not identical. The update clears previous concerns that were used by insurers to deny coverage for Makena prescriptions. | Comment!
KV.B vs. ETF Alternatives
Other News & PR